SampR advises on NYLIM Jacob Ballas private equity investment in Vivimed Labs

Hyderabad-based Vivimed Labs has raised Rs. 67 crore ($13.5 million) from private equity firm NYLIM Jacob Ballas Fund III. 

S&R Associates advised Jacob Ballas with a team led by Partner Uday Walia along with Simran Dhir and Radhika Agrawal.

Vivimed Labs were represented by its in-house team.

NYLIM Jacob Ballas India Fund has invested Rs. 67 crore to subscribe to compulsorily convertible preference shares (to be converted within a period of 18 months) at a price of Rs. 315 per unit, picking up 13.2 percent stake, according to VCCircle.

Vivimed has also raised Rs. 60 crore from private equity firm Kitara Capital.

The fundraising will finance Vivimed’s ongoing expansion plans for speciality chemicals at its existing locations in Bidar (Karnataka), a green field project off Vizag at Pydibhimavaram (Andhra Pradesh) and a USFDA-compliant facility for pharmaceuticals at Choutuppal near Hyderabad, as well as acquisitions of pharmaceutical marketing companies in India and the overseas acquisition of an API manufacturing company in Europe.

Dealcurry reports, Vivimed has acquired Kolkata based eye care pharma firm, Klar Sehen. Vivimed has also acquired 50 percent stake in AP based - Octtantis Nobel Labs to foray into domestic pharma retail space. Vivimed is also acquiring Spain-based Uquifa SA for $55 million.